Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRL-302 (BRL Medicine Inc.)
- Development stage
- Unknown
- Lead developer
- BRL Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BRL-302 (BCMA UCAR-T) is an allogeneic, universal chimeric antigen receptor T-cell (CAR-T) therapy developed by BRL Medicine. It is engineered to target B-cell maturation antigen (BCMA, TNFRSF17), which is highly expressed on antibody-producing plasma cells and plasmablasts. Developed using BRL Medicine's proprietary TyUCell® universal cell platform, BRL-302 utilizes multiplex gene editing to enable immune evasion and prevent graft-versus-host disease (GVHD) and host-versus-graft (HvG) reactions, allowing off-the-shelf use without requiring deep lymphodepletion. BRL-302 is primarily being developed for the treatment of refractory neurological autoimmune diseases, including neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis, and myasthenia gravis, as well as lupus nephritis.
- Other names
- BCMA UCAR-TBCMA-UCARTuniversal BCMA CAR-T
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on BRL-302 (BRL Medicine Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRL-302 (BRL Medicine Inc.).